{'fraction_non_alphanumeric': 0.024175824175824177, 'fraction_numerical': 0.0014652014652014652, 'mean_word_length': 5.2949308755760365, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hypothalamic control of fertility.


 8 world experts attended the 1st International Planned Parenthood Federation Cambridge workshop to discuss the hypothalamic control of fertility, reviewing the state of current work, presenting their latest findings, and suggesting possible new lines of research. Combined oral contraceptives are thought to act largely by a feedback mechanism on the pituitary, preventing the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH). A possible new contraceptive could be developed which would act at the higher level of the hypothalamus by interfering with the action of gonadotropin-releasing hormones. S.S.C. Yen from La Jolla, California, reported on the physiological effects of synthetic releasing hormone (FSH-RH/LH-RH) in groups of human subjects. A.V. Schally from New Orleans showed that the releasing hormone could produce ovulation in women with amenorrhea of hypothalamic origin, and seems to be of benefit in those conditions where insufficient pituitary gonadotropin secretion is suspected. Synthetic releasing hormone or its analogues may be useful for control of human fertility by disruption of the menstrual cycle, induction of ovulation at a known time, use of synthetic inhibitors to releasing hormone, or possibly with an immunological approach. Much basic research must first be done.
